Multiple system atrophy: A prototypical synucleinopathy for disease-modifying therapeutic strategies

Neurobiology of Disease

Volumn 67, Issue , 2014, Pages 133-139

  Fernagut, Pierre Olivier ^a   Dehay, Benjamin ^a   Maillard, Aline ^b   Bezard, Erwan ^a,b   Perez, Paul ^b   Traon, Anne Pavy Le ^c   Rascol, Olivier ^c,d,e   Foubert Samier, Alexandra ^a,b   Tison, François ^a,b   Meissner, Wassilios G ^a,b  

^a INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

^e INSERM   (France)

Author keywords

Alpha synuclein; Disease modifying; Multiple system atrophy; Synucleinopathies; Therapeutic strategies

Indexed keywords

ALPHA SYNUCLEIN; LITHIUM; MINOCYCLINE; PLACEBO; RASAGILINE; RIFAMPICIN;

DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; NEUROPROTECTION; PARKINSON DISEASE; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; SHY DRAGER SYNDROME; BRAIN; CLINICAL TRIAL (TOPIC); METABOLISM; MULTIPLE SYSTEM ATROPHY; PATHOLOGY;

ALPHA-SYNUCLEIN; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE;

EID: 84899112437     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.03.021     Document Type: Review

References (89)

1. Ahlskog J.E., Uitti R.J. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?. Neurology 2010, 74:1143-1148.
2. Al-Chalabi A., et al. Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS One 2009, 4:e7114.
3. Asi Y.T., et al. Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia 2014, 10.1002/glia.22653.
4. Bensimon G., et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009, 132:156-171.
5. Campbell B.C., et al. The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J. Neurochem. 2001, 76:87-96.
6. Chartier-Harlin M.C., et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
7. Damon-Perriere N., et al. Assessment of the Scopa-Aut questionnaire in multiple system atrophy: relation to UMSARS scores and progression over time. Parkinsonism Relat. Disord. 2012, 18:612-615.
8. Dehay B., Bezard E. New animal models of Parkinson's disease. Mov. Disord. 2011, 26:1198-1205.
9. Dehay B., et al. Lysosomal impairment in Parkinson's disease. Mov. Disord. 2013, 28:725-732.
10. Diguet E., et al. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur. J. Neurosci. 2004, 19:3266-3276.
11. Dodel R., et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov. Disord. 2010, 25:97-107.
12. Evans J.R., Barker R.A. Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease. Expert. Opin. Pharmacother. 2011, 12:1249-1258.
13. Fernagut P.O., Tison F. Animal models of multiple system atrophy. Neuroscience 2012, 211:77-82.
14. Foulds P.G., et al. Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J. 2011, 25:4127-4137.
15. Fuchs J., et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007, 68:916-922.
16. Gilman S., Wenning G.K., Low P.A., Brooks D.J., Mathias C.J., Trojanowski J.Q., Wood N.W., Colosimo C., Durr A., Fowler C.J., Kaufmann H., Klockgether T., Lees A., Poewe W., Quinn N., Revesz T., Robertson D., Sandroni P., Seppi K., Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. Mov. Disord. 2008, S255.
17. Gu M., et al. Mitochondrial respiratory chain function in multiple system atrophy. Mov. Disord. 1997, 12:418-422.
18. Halliday G.M., et al. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 2011, 122:187-204.
19. Hishikawa N., et al. Dorfin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis. Am. J. Pathol. 2003, 163:609-619.
20. Holford N.H., Nutt J.G. Interpreting the results of Parkinson's disease clinical trials: time for a change. Mov. Disord. 2011, 26:569-577.
21. Holmberg B., et al. Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov. Disord. 2007, 22:1138-1144.
22. Ibanez P., et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004, 364:1169-1171.
23. Jin H., et al. Analyses of copy number and mRNA expression level of the alpha-synuclein gene in multiple system atrophy. J. Med. Dent. Sci. 2008, 55:145-153.
24. Kahle P.J., et al. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep. 2002, 3:583-588.
25. Kawamoto Y., et al. Accumulation of 14-3-3 proteins in glial cytoplasmic inclusions in multiple system atrophy. Ann. Neurol. 2002, 52:722-731.
26. Kawamoto Y., et al. Accumulation of HtrA2/Omi in neuronal and glial inclusions in brains with alpha-synucleinopathies. J. Neuropathol. Exp. Neurol. 2008, 67:984-993.
27. Kim Y.M., et al. Proteasome inhibition induces alpha-synuclein SUMOylation and aggregate formation. J. Neurol. Sci. 2011, 307:157-161.
28. Kingsbury A.E., et al. Alteration in alpha-synuclein mRNA expression in Parkinson's disease. Mov. Disord. 2004, 19:162-170.
29. Kollensperger M., et al. Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. Eur. J. Neurol. 2007, 14:66-72.
30. Kovacs G.G., et al. Natively unfolded tubulin polymerization promoting protein TPPP/p25 is a common marker of alpha-synucleinopathies. Neurobiol. Dis. 2004, 17:155-162.
31. Lashuel H.A., et al. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 2013, 14:38-48.
32. Lipp A., et al. Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. Arch. Neurol. 2009, 66:742-750.
33. Luk K.C., et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338:949-953.
34. Makioka K., et al. Activation and alteration of lysosomes in multiple system atrophy. Neuroreport 2012, 23:270-276.
35. Mandler M., et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol. 2014, 10.1007/s00401-014-1256-4.
36. Masuda-Suzukake M., et al. Prion-like spreading of pathological alpha-synuclein in brain. Brain 2013, 136:1128-1138.
37. May S., et al. Potential outcome measures and trial design issues for multiple system atrophy. Mov. Disord. 2007, 22:2371-2377.
38. Meissner W.G., et al. Priorities in Parkinson's disease research. Nat. Rev. Drug Discov. 2011, 10:377-393.
39. Meissner W.G., et al. Assessment of quality of life with the multiple system atrophy health-related quality of life scale. Mov. Disord. 2012, 27:1574-1577.
40. Miki Y., et al. Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions. Neuropathology 2011, 31:561-568.
41. Miller D.W., et al. Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J. Neural Transm. 2005, 112:1613-1624.
42. Mori F., et al. Accumulation of NEDD8 in neuronal and glial inclusions of neurodegenerative disorders. Neuropathol. Appl. Neurobiol. 2005, 31:53-61.
43. Murakami T., et al. PINK1, a gene product of PARK6, accumulates in alpha-synucleinopathy brains. J. Neurol. Neurosurg. Psychiatry 2007, 78:653-654.
44. Nalls M.A., et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377:641-649.
45. Novak P., et al. Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol. 2012, 12:131.
46. Odagiri S., et al. Autophagic adapter protein NBR1 is localized in Lewy bodies and glial cytoplasmic inclusions and is involved in aggregate formation in alpha-synucleinopathy. Acta Neuropathol. 2012, 124:173-186.
47. Olanow C.W., Rascol O. The delayed-start study in Parkinson disease: can't satisfy everyone. Neurology 2010, 74:1149-1150.
48. Olanow C.W., Schapira A.H. Therapeutic prospects for Parkinson disease. Ann. Neurol. 2013, 74:337-347.
49. Olanow C.W., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 2009, 361:1268-1278.
50. Osaki Y., et al. A validation exercise on the new consensus criteria for multiple system atrophy. Mov. Disord. 2009, 24:2272-2276.
51. Paviour D.C., et al. Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain 2006, 129:1040-1049.
52. Paviour D.C., et al. MRI derived brain atrophy in PSP and MSA-P. Determining sample size to detect treatment effects. J Neurol. 2007, 254:478-481.
53. Pellecchia M.T., et al. Progression of striatal and extrastriatal degeneration in multiple system atrophy: a longitudinal diffusion-weighted MR study. Mov. Disord. 2011, 26:1303-1309.
54. Peran P., et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010, 133:3423-3433.
55. Poewe W., et al. A randomized, placebo-controlled clinical trial to assess the effects of rasagiline in patients with multiple system atrophy of the Parkinsonian subtype. Mov. Disord. 2012, 27.
56. Ravina B., et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005, 64:208-215.
57. Recasens A., et al. Lewy body extracts from Parkinson's disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 2014, 75:351-362.
58. Reyes J.F., et al. Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 2014, 62:387-398.
59. Sacca F., et al. A randomized clinical trial of lithium in multiple system atrophy. J. Neurol. 2013, 260:458-461.
60. Sarkar S., et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 2005, 170:1101-1111.
61. Scholz S.W., et al. SNCA variants are associated with increased risk for multiple system atrophy. Ann. Neurol. 2009, 65:610-614.
62. Schrag A., et al. Measuring health-related quality of life in MSA: the MSA-QoL. Mov. Disord. 2007, 22:2332-2338.
63. Schwarz L., et al. Involvement of macroautophagy in multiple system atrophy and protein aggregate formation in oligodendrocytes. J. Mol. Neurosci. 2012, 47:256-266.
64. Seppi K., et al. Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. Mov. Disord. 2006, 21:847-852.
65. Shao C.Y., et al. Atypical protein kinase C in neurodegenerative disease II: PKCiota/lambda in tauopathies and alpha-synucleinopathies. J. Neuropathol. Exp. Neurol. 2006, 65:327-335.
66. Shults C.W., et al. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J. Neurosci. 2005, 25:10689-10699.
67. Singleton A.B., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
68. Song Y.J., et al. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J. Neuropathol. Exp. Neurol. 2009, 68:1073-1083.
69. Spillantini M.G., Goedert M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. N. Y. Acad. Sci. 2000, 920:16-27.
70. Stefanova N., et al. Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. J. Neurosci. Res. 2004, 78:87-91.
71. Stefanova N., et al. Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov. Disord. 2007, 22:2196-2203.
72. Stefanova N., et al. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp. Neurol. 2008, 210:421-427.
73. Stefanova N., et al. Multiple system atrophy: an update. Lancet Neurol. 2009, 8:1172-1178.
74. Tanikawa S., et al. Endosomal sorting related protein CHMP2B is localized in Lewy bodies and glial cytoplasmic inclusions in alpha-synucleinopathy. Neurosci. Lett. 2012, 527:16-21.
75. Tanji K., et al. Immunohistochemical localization of NUB1, a synphilin-1-binding protein, in neurodegenerative disorders. Acta Neuropathol. 2007, 114:365-371.
76. Tanji K., et al. Alteration of autophagosomal proteins in the brain of multiple system atrophy. Neurobiol. Dis. 2012, 49C:190-198.
77. Tokuda T., et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 75:1766-1772.
78. Ubhi K., et al. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport 2008, 19:1271-1276.
79. Ulusoy A., et al. Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease. Prog. Brain Res. 2010, 184:89-111.
80. Uryu K., et al. Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies. Am. J. Pathol. 2006, 168:947-961.
81. Wakabayashi K., et al. Immunocytochemical localization of synphilin-1, an alpha-synuclein-associated protein, in neurodegenerative disorders. Acta Neuropathol. 2002, 103:209-214.
82. Watts J.C., et al. Transmission of multiple system atrophy prions to transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:19555-19560.
83. Wenning G.K., et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov. Disord. 2004, 19:1391-1402.
84. Wenning G.K., et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 2013, 12:264-274.
85. Winner B., et al. In vivo demonstration that {alpha}-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4194-4199.
86. Wong M.B., et al. SUMO-1 is associated with a subset of lysosomes in glial protein aggregate diseases. Neurotox. Res. 2013, 23:1-21.
87. Wu D.C., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 2002, 22:1763-1771.
88. Yazawa I., et al. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005, 45:847-859.
89. Zhao T., et al. FBXO7 immunoreactivity in alpha-synuclein-containing inclusions in Parkinson disease and multiple system atrophy. J. Neuropathol. Exp. Neurol. 2013, 72:482-488.